Is Eli Lilly Stock a Buy?

Type 2 diabetes and obesity have become an increasing global healthcare problem, reaching near crisis proportions in the United States. The arrival of GLP-1 agonists, drugs that mimic hormones to slow digestion and quell hunger, offers a potential solution and has created one of the pharmaceutical industry's most lucrative opportunities in recent history.Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales of GLP-1 agonists could grow at a 33% annualized rate, reaching $471 billion by 2032.Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool